J. Boutin

发表

Microfluidic platform for optimization of crystallization conditions

Shuheng Zhang, Charline J. J. Gerard, A. Ikni, 2017 .

The Emergence of Selective 5-HT2B Antagonists Structures, Activities and Potential Therapeutic Applications [General Reviews]

J. Boutin, G. Poissonnet, J. Parmentier, 2004 .

VHH characterization.Recombinant VHHs: Production, characterization and affinity.

G. Ferry, J. Boutin, S. Cianférani, 2020, Analytical biochemistry.

Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads

J. Fauchère, J. Boutin, J. Henlin, 1998 .

Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT1 and MT2 receptors

O. Nosjean, J. Boutin, C. Legros, 2019, Pharmacology research & perspectives.

High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with Anti-Diabetic Efficacy in db/db Mice

O. Nosjean, J. Boutin, P. Renard, 2013, PloS one.

Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence

Philippe Delagrange, Marc Baroncini, Vincent Prevot, 2010, Journal of pineal research.

Natural ligands of PPARγ:: Are prostaglandin J2 derivatives really playing the part?

O. Nosjean, J. Boutin, 2002 .

Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?

O. Nosjean, J. Boutin, 2002, Cellular signalling.

Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma.

O. Nosjean, G. Ferry, J. Boutin, 2005, Biochemical and biophysical research communications.

Identification of the Melatonin-binding SiteMT 3 as the Quinone Reductase 2*

O. Nosjean, J. Fauchère, J. Boutin, 2000, The Journal of Biological Chemistry.

Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors.

G. Ferry, J. Boutin, B. Pfeiffer, 2011, Life sciences.

General lack of structural characterization of chemically synthesized long peptides

H. Vaudry, J. Boutin, A. van Dorsselaer, 2019, Protein science : a publication of the Protein Society.

Melanin-concentrating hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

J. Boutin, V. Audinot, Yumi Saito, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models

J. Boutin, A. Ktorza, V. Audinot, 2012, Front. Endocrin..

S38151 [p-guanidinobenzoyl-[Des-Gly10]-MCH(7-17)] is a potent and selective antagonist at the MCH1 receptor and has anti-feeding properties in vivo

O. Nosjean, J. Fauchère, J. Boutin, 2009, Peptides.

Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa.

H. Vaudry, J. Boutin, M. Tena-Sempere, 2011, Journal of Medicinal Chemistry.

Apigenin and Luteolin Regulate Autophagy by Targeting NRH-Quinone Oxidoreductase 2 in Liver Cells

J. Boutin, E. Janda, V. Mollace, 2021, Antioxidants.

High-throughput screening assay for new ligands at human melatonin receptors

J. Boutin, H. Su, Ming-Wei Wang, 2008, Acta Pharmacologica Sinica.

Quinone reductase 2 as a promising target of melatonin therapeutic actions

J. Boutin, 2016, Expert opinion on therapeutic targets.

Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .

O. Nosjean, J. Nicolas, J. Boutin, 2001, Biochemical pharmacology.

Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.

G. Ferry, J. Boutin, P. Delagrange, 2005, The Biochemical journal.

Identification of catalytic and non‐catalytic activity inhibitors against PRC2‐EZH2 complex through multiple high‐throughput screening campaigns

O. Nosjean, J. Boutin, P. Renard, 2020, Chemical biology & drug design.

Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.

J. Boutin, S. Goldstein, C. Brulé, 2011, Bioorganic & medicinal chemistry.

UDP-GLUCURONOSY LMSFERASE

J. Boutin, 1987 .

NPY receptor subtype in the rabbit isolated ileum

J. Nicolas, J. Boutin, M. Félétou, 1999, British journal of pharmacology.

Assessment of some tools for the characterization of the human osteoarthritic cartilage proteome.

G. Ferry, J. Boutin, F. De Ceuninck, 2005, Journal of biomolecular techniques : JBT.

Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation

G. Ferry, J. Boutin, P. Valet, 2003, The Journal of Biological Chemistry.

Melatonin controversies, an update

J. Boutin, R. Jockers, 2020, Journal of pineal research.

Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: a new kinetic approach for the study of induction and specificity.

G. Siest, J. Boutin, B. Antoine, 1994, Journal of pharmaceutical sciences.

VHH characterization. Comparison of recombinant with chemically synthesized anti‐HER2 VHH

G. Ferry, J. Boutin, S. Cianférani, 2019, Protein science : a publication of the Protein Society.

X‐ray structural studies of quinone reductase 2 nanomolar range inhibitors

G. Ferry, J. Boutin, A. Mesecar, 2011, Protein science : a publication of the Protein Society.

Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.

J. Boutin, Barbara Calamini, A. Mesecar, 2008, The Biochemical journal.

Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors

J. Boutin, P. Renard, A. Ktorza, 2010, Journal of enzyme inhibition and medicinal chemistry.

Synthesis of Aromatic Analogs of 8(S)-HETE and Their Biological Evaluation as Activators of the PPAR Nuclear Receptors

J. Boutin, P. Renard, R. Grée, 2006 .

On the Organization of a Drug Discovery Platform

O. Nosjean, G. Ferry, J. Boutin, 2018, Drug Discovery - Concepts to Market.

Synthesis, chiral resolution, absolute configuration assignment and pharmacological evaluation of a series of melatoninergic ligands

O. Nosjean, J. Boutin, P. Delagrange, 2014 .

Substrate Specificity and Inhibition Studies of Human Serotonin N- Acetyltransferase*

J. Fauchère, E. Jacoby, G. Ferry, 2000 .

Chromatographic assay and peptide substrate characterization of partially purified farnesyl- and geranylgeranyltransferases from rat brain cytosol.

J. Fauchère, J. Boutin, W. Marande, 1998, Archives of biochemistry and biophysics.

Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction.

Charline J. J. Gerard, G. Ferry, L. Vuillard, 2017, Acta crystallographica. Section F, Structural biology communications.

MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice

G. Ferry, J. Boutin, Lukasz P. Frankiewicz, 2021, Molecules.

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.

J. Boutin, A. Ktorza, B. Staels, 2008, Bioorganic & medicinal chemistry letters.

Physico-chemical and biological analysis of true combinatorial libraries.

J. Fauchère, J. Boutin, P. Lambert, 1999, Journal of chromatography. B, Biomedical sciences and applications.

New biologically active linear triterpenes from the bark of three new-caledonian Cupaniopsis species

O. Nosjean, J. Boutin, P. Renard, 2005 .

Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose.

G. Ferry, J. Boutin, C. Pecqueur, 2006, The Biochemical journal.

In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats.

J. Boutin, F. Meunier, P. Lambert, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs.

J. Nicolas, J. Boutin, P. Delagrange, 1999, The Journal of pharmacology and experimental therapeutics.

The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion

J. Boutin, C. Legros, 2019, Pharmacology research & perspectives.

In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones.

G. Ferry, J. Boutin, F. Nepveu, 2015, Free radical biology & medicine.

Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.

M. Millan, D. Cussac, A. Gobert, 2001, The Journal of pharmacology and experimental therapeutics.

Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform.

J. Nicolas, J. Boutin, V. Audinot, 2003, The Biochemical journal.

Three-Dimensional Quantitative Structure–Activity Relationship of MT3 Melatonin Binding Site Ligands: A Comparative Molecular Field Analysis

J. Boutin, P. Renard, P. Chavatte, 2007 .

Appetite-boosting property of pro-melanin-concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is associated with proteolytic resistance.

J. Boutin, V. Audinot, T. Suply, 2002, The Journal of pharmacology and experimental therapeutics.

Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.

G. Ferry, J. Boutin, P. Delagrange, 2005, Biochemical pharmacology.

Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors.

J. Boutin, D. Lesieur, P. Renard, 2004, Biochemical pharmacology.

New selective ligands of human cloned melatonin MT1 and MT2 receptors

J. Boutin, D. Lesieur, P. Renard, 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

Regulation of murine airway responsiveness by endothelial nitric oxide synthase.

P. Huang, J. Boutin, F. Cogé, 2001, American journal of physiology. Lung cellular and molecular physiology.

Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT 3

G. Ferry, J. Boutin, P. Delagrange, 2004, FEBS letters.

New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists

O. Nosjean, J. Boutin, P. Delagrange, 2017, International journal of molecular sciences.

Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G‐protein coupled state

O. Nosjean, J. Boutin, P. Delagrange, 2014, British journal of pharmacology.

Uncoupling Protein-3 (UCP3) mRNA Expression in Reconstituted Human Muscle after Myoblast Transplantation in RAG2−/−/γc/C5− Immunodeficient Mice*

J. Boutin, V. Mouly, J. D. Di Santo, 2002, The Journal of Biological Chemistry.

Melatonin from Cerebrospinal Fluid but Not from Blood Reaches Sheep Cerebral Tissues Under Physiological Conditions

J. Boutin, B. Malpaux, D. Chesneau, 2014, Journal of neuroendocrinology.

MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co‐substrate

G. Ferry, J. Boutin, P. Delagrange, 2008, Journal of pineal research.

Limitations of the Coupling of Amino Acid Mixtures for the Preparation of Equimolar Peptide Libraries

J. Fauchère, J. Boutin, J. Henlin, 2004, Molecular Diversity.

Expression and regulation of the nuclear receptor RORα in human vascular cells

J. Boutin, J. Mariani, A. Tedgui, 2002 .

Relationship between the cellular accumulation and the cytotoxicity of S12363, a new vinca alkaloid derivative

J. Boutin, G. Lavielle, A. Pierré, 2004, Cancer Chemotherapy and Pharmacology.

Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.

J. Boutin, P. Renard, R. Grée, 2005, Bioorganic & medicinal chemistry letters.

Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.

O. Nosjean, J. Boutin, B. Pfeiffer, 2009, Journal of natural products.

Secure and Sustainable Sourcing of Plant Tissues for the Exhaustive Exploration of Their Chemodiversity

J. Boutin, H. Rogez, S. Darnet, 2020, Molecules.

Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Conjugations of phenolic and monoterpenoid aglycones in control and induced rats and guinea pigs.

G. Siest, J. Boutin, A. Cartier, 1985, Biochemical pharmacology.

Use of the main tyrosine protein kinase activity purified from HL-60 in the search for a new class of anticancer compounds.

G. Ferry, J. Boutin, A. Ernould, 1990, Anticancer research.

Melanin-concentrating hormone and its receptors: state of the art.

J. Fauchère, J. Nicolas, J. Boutin, 2002, Canadian journal of physiology and pharmacology.

SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study.

J. Boutin, V. Audinot, E. Canet, 2001, The Journal of pharmacology and experimental therapeutics.

How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends

J. Boutin, 2018 .

Heterogeneity of hepatic UDP-glucuronosyltransferase activities: investigations of isoenzymes involved in p-nitrophenol glucuronidation.

G. Siest, J. Boutin, B. Antoine, 1993, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

Assessments of cellular melatonin receptor signaling pathways: &bgr;‐arrestin recruitment, receptor internalization, and impedance variations

O. Nosjean, J. Boutin, C. Legros, 2018, European journal of pharmacology.

NRH:quinone reductase 2: an enzyme of surprises and mysteries.

G. Ferry, J. Boutin, P. Delagrange, 2005, Biochemical pharmacology.

Endothelin‐1 inhibits TNFα‐induced iNOS expression in 3T3‐F442A adipocytes

J. Boutin, M. Lafontan, J. Galitzky, 2003 .

Molecular tools to study melatonin pathways and actions.

G. Ferry, J. Boutin, P. Delagrange, 2005, Trends in pharmacological sciences.

Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3*

G. Ferry, J. Boutin, J. Hickman, 2003, The Journal of Biological Chemistry.

A Putative New Melatonin Binding Site in Sheep Brain, MTx: Preliminary Observations and Characteristics

J. Boutin, P. Delagrange, J. Leprince, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Caloxin-derived peptides for the inhibition of plasma membrane calcium ATPases

G. Ferry, J. Boutin, J. Leprince, 2022, Peptides.

NPY receptor subtypes involved in the contraction of the proximal colon of the rat

J. Fauchère, J. Nicolas, J. Boutin, 1998, Regulatory Peptides.

New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors.

O. Nosjean, G. Ferry, J. Boutin, 2004, European journal of biochemistry.

A quantitative assay for lysosomal acidification rates in human osteoclasts.

O. Nosjean, M. Karsdal, J. Boutin, 2011, Assay and drug development technologies.

[125I]‐S36057: a new and highly potent radioligand for the melanin‐concentrating hormone receptor

J. Fauchère, J. Boutin, V. Audinot, 2001, British journal of pharmacology.

Genomic organization and characterization of splice variants of the human histamine H3 receptor.

J. Boutin, V. Audinot, F. Cogé, 2001, The Biochemical journal.

New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.

O. Nosjean, J. Boutin, P. Delagrange, 2014, Bioorganic & medicinal chemistry.

Molecular pharmacology of adipocyte-secreted autotaxin.

G. Ferry, J. Boutin, Benjamin Fould, 2008, Chemico-biological interactions.

Chemical composition and antibacterial action of Stryphnodendron pulcherrimum bark extract, “barbatimão” species: Evaluation of its use as a topical agent

J. Boutin, M. Monteiro, J. Souza, 2021 .

Description of the constitutive activity of cloned human melatonin receptors hMT1 and hMT2 and discovery of inverse agonists

O. Nosjean, J. Boutin, P. Delagrange, 2012, Journal of pineal research.

Therapeutic Potential of Melatonin Ligands

J. Boutin, P. Delagrange, 2006, Chronobiology international.

In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles.

J. Boutin, Franck B. Riquet, J. Galizzi, 2003, Biochemical and biophysical research communications.

Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).

J. Boutin, P. Delagrange, S. Yous, 2015, European journal of medicinal chemistry.

A microplate assay for the screening of ADAMTS-4 inhibitors.

G. Ferry, J. Boutin, Jean-Claude Ortuno, 2006, Matrix biology : journal of the International Society for Matrix Biology.

Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel

G. Ferry, J. Boutin, P. Ducrot, 2019, Toxicon: X.

New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation.

J. Boutin, P. Delagrange, S. Yous, 2017, European journal of medicinal chemistry.

Synthesis and Pharmacological Evaluation of a series of the Agomelatine Analogues as Melatonin MT1/MT2 Agonist and 5‐HT2C Antagonist

O. Nosjean, J. Boutin, P. Delagrange, 2013, ChemMedChem.

Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂.

O. Nosjean, J. Boutin, P. Delagrange, 2012, European journal of pharmacology.

Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.

J. Boutin, D. Hazlerigg, P. Delagrange, 2008, Biochemical pharmacology.

Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87)

G. Ferry, J. Boutin, P. Delagrange, 2002, Cellular and Molecular Life Sciences CMLS.

airway responsiveness to histamine in guinea pigs Nitric oxide derived from sympathetic nerves regulates

J. Boutin, Paul L Huang, F. Cogé, 2013 .

Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption

O. Nosjean, M. Karsdal, J. Boutin, 2010, BMC musculoskeletal disorders.

Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.

G. Ferry, J. Boutin, M. Viaud-Massuard, 2008, European journal of medicinal chemistry.

Ligand modulation of [ 35S]GTP?S binding at human a 2A, a 2B and a 2C adrenoceptors

M. Millan, A. Newman-Tancredi, J. Nicolas, 2002 .

S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological Tool

G. Ferry, J. Boutin, J. Pradère, 2008, Journal of Pharmacology and Experimental Therapeutics.

Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist.

H. Vaudry, J. Boutin, J. Chuquet, 2012, Journal of medicinal chemistry.

Therapeutic Perspectives for Melatonin Agonists and Antagonists

J. Atkinson, J. Boutin, D. Lesieur, 2003, Journal of neuroendocrinology.

Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay.

J. Nicolas, J. Boutin, P. Chomarat, 2005, Cellular signalling.

Image-free assessment of protein translocation in live cells.

O. Nosjean, J. Boutin, S. Derick, 2009, Current opinion in pharmacology.

Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization.

G. Ferry, J. Boutin, P. Valet, 2008, The Journal of biological chemistry.

Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.

J. Boutin, P. Delagrange, S. Yous, 2011, European journal of medicinal chemistry.

Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.

O. Nosjean, J. Boutin, P. Delagrange, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.

J. Boutin, P. Renard, P. Chavatte, 2010, Bioorganic & medicinal chemistry.

Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.

J. Boutin, D. Lesieur, P. Renard, 2008, Bioorganic & medicinal chemistry.

Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species.

G. Ferry, J. Boutin, P. Delagrange, 2004, Protein expression and purification.

Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands.

J. Nicolas, J. Boutin, P. Delagrange, 2003, Bioorganic & medicinal chemistry.

Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.

J. Boutin, D. Lesieur, P. Renard, 2003, Bioorganic & Medicinal Chemistry.

Substrate Specificity and Inhibition Studies of Human SerotoninN-Acetyltransferase*

J. Fauchère, E. Jacoby, G. Ferry, 2000, The Journal of Biological Chemistry.

Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors.

J. Nicolas, J. Boutin, P. Renard, 2000, Bioorganic & medicinal chemistry.

Journal of pineal research guideline for authors: Defining and characterizing melatonin targets

J. Boutin, E. Cecon, R. Jockers, 2020, Journal of pineal research.

W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway

O. Nosjean, J. Boutin, P. Renard, 2017, Acta Pharmacologica Sinica.

Natural Inhibitors of the RhoA-p115 Complex from the Bark of Meiogyne baillonii.

G. Ferry, J. Boutin, B. Pfeiffer, 2018, Journal of natural products.

Association of NQO2 With UDP-Glucuronosyltransferases Reduces Menadione Toxicity in Neuroblastoma Cells

G. Ferry, J. Boutin, F. Nepveu, 2021, Frontiers in Pharmacology.

Insights into the redox cycle of human quinone reductase 2

G. Ferry, J. Boutin, P. Delagrange, 2011, Free radical research.

Old and new inhibitors of quinone reductase 2.

G. Ferry, J. Boutin, P. Delagrange, 2010, Chemico-biological interactions.

Recombinant Human Melatonin Receptor MT1 Isolated in Mixed Detergents Shows Pharmacology Similar to That in Mammalian Cell Membranes

O. Nosjean, G. Ferry, J. Boutin, 2014, PloS one.

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D 2 -Like Receptor and (cid:1) 1 / (cid:1) 2 -Adrenoceptor

M. Millan, D. Cussac, A. Newman-Tancredi, 2002 .

Hamster Melatonin Receptors: Cloning and Binding Characterization of MT1 and Attempt to Clone MT2

O. Nosjean, J. Boutin, P. Delagrange, 2018, International journal of molecular sciences.

Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.

J. Boutin, D. Lesieur, P. Renard, 2003, Journal of medicinal chemistry.

S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.

M. Millan, D. Cussac, A. Newman-Tancredi, 2000, The Journal of pharmacology and experimental therapeutics.

Approach to the specificity and selectivity between D2 and D3 receptors by mutagenesis and binding experiments part I: Expression and characterization of D2 and D3 receptor mutants

O. Nosjean, G. Ferry, J. Boutin, 2022, Protein science : a publication of the Protein Society.

Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mammalian species.

G. Siest, J. Boutin, S. Fournel, 1987, Comparative biochemistry and physiology. B, Comparative biochemistry.

Assessment of a high-throughput screening methodology for the measurement of purified UCP1 uncoupling activity.

G. Ferry, J. Boutin, B. Miroux, 2006, Analytical biochemistry.

UDP-glucuronosyltransferase(s) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of triton X-100 activation.

G. Siest, J. Boutin, J. Thomassin, 1985, Pharmacological research communications.

The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications.

J. Boutin, G. Poissonnet, J. Parmentier, 2004, Mini reviews in medicinal chemistry.

Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.

J. Boutin, P. Renard, P. Delagrange, 2004, European journal of medicinal chemistry.

Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes

Pierre Ducrot, Emmanuelle Lautié, Olivier Russo, 2020, Frontiers in Pharmacology.

New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity.

J. Boutin, G. Lavielle, A. Pierré, 1991, Journal of medicinal chemistry.

Design and Synthesis of Indole and Tetrahydroisoquinoline Hydantoin Derivatives as Human Chymase Inhibitors

G. Ferry, J. Boutin, P. Renard, 2004, Journal of enzyme inhibition and medicinal chemistry.

New ligands at the melatonin binding site MT(3).

G. Ferry, J. Boutin, P. Delagrange, 2006, European journal of medicinal chemistry.

Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors.

J. Nicolas, J. Boutin, P. Delagrange, 2000, Journal of medicinal chemistry.

Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity

J. Boutin, A. Ktorza, B. Staels, 2012, ChemMedChem.

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization

E. Hirsch, G. Ferry, J. Boutin, 2018, Molecular Pharmacology.

Melatonin receptor ligands: A pharmaco‐chemical perspective

C. Sotriffer, J. Boutin, P. Witt-Enderby, 2020, Journal of pineal research.

Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).

J. Boutin, D. Lesieur, P. Renard, 2002, Journal of medicinal chemistry.

Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.

J. Boutin, D. Lesieur, P. Renard, 2006, Bioorganic & medicinal chemistry.

Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.

J. Boutin, G. Lavielle, A. Pierré, 1990, Anticancer research.

Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.

J. Boutin, M. Mor, P. Delagrange, 2015, Journal of medicinal chemistry.

A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects.

J. Fauchère, G. Ferry, J. Boutin, 1998, European journal of pharmacology.

Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of Stryphnodendron pulcherrimum (Willd.) Hochr

M. Eberlin, J. Boutin, J. Wolfender, 2021, Metabolites.

Inhibition of microsomal NAD(P)H oxidation by Triton X-100.

J. Boutin, 1986, Journal of biochemical and biophysical methods.

Peroxisome Proliferator-activated Receptor γ (PPARγ) as a Molecular Target for the Soy Phytoestrogen Genistein*

J. Boutin, C. Löwik, V. Audinot, 2003, The Journal of Biological Chemistry.

Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein.

J. Boutin, C. Löwik, V. Audinot, 2003, The Journal of biological chemistry.

Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2

G. Ferry, J. Boutin, F. Nepveu, 2018, Free radical biology & medicine.

Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states.

G. Ferry, J. Boutin, M. Antoine, 2009, Biochemistry.

Studies of the potency of protein kinase inhibitors on ATPase activities.

G. Ferry, J. Boutin, J. Barret, 1993, Chemico-biological interactions.

Assay of tyrosine protein kinase activity from HL-60 by high-performance liquid chromatography for specificity studies.

G. Ferry, J. Boutin, A. Ernould, 1990, Analytical biochemistry.

Integrated system for the screening of the specificity of protein kinase inhibitors.

G. Ferry, J. Boutin, J. Barret, 1993, Biochemical pharmacology.

High-Capacity Screening of Arylalkylamine N-Acetyltransferase Inhibitors using a High-Performance Liquid Chromatography System

G. Ferry, J. Boutin, 2000, Journal of biomolecular screening.

Rat liver microsomal 3 alpha-hydroxysteroid dehydrogenase and dihydrodiol dehydrogenase: solubilization, separation and partial purification.

J. Boutin, P. Talalay, M. Shikita, 1986, Biochemical and biophysical research communications.

Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors

O. Nosjean, J. Boutin, P. Delagrange, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.

J. Boutin, P. Delagrange, S. Yous, 2016, European journal of medicinal chemistry.

Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors

G. Ferry, J. Boutin, P. Chavatte, 2002, Journal of enzyme inhibition and medicinal chemistry.

Screening of Ligand Binding on Melatonin Receptor Using Non-Peptide Combinatorial Libraries

J. Fauchère, J. Nicolas, J. Boutin, 2000, Journal of receptor and signal transduction research.

Structure and expression of the human histamine H4-receptor gene.

J. Boutin, F. Cogé, J. Galizzi, 2001, Biochemical and biophysical research communications.

Tyrosine protein kinase assays.

J. Boutin, 1996, Journal of chromatography. B, Biomedical applications.

Tyrosine protein kinase inhibition and cancer.

J. Boutin, 1994, The International journal of biochemistry.

Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60.

G. Ferry, J. Boutin, J. Barret, 1993, European journal of biochemistry.

GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation

H. Hamm, G. Ferry, J. Boutin, 2018, Proceedings of the National Academy of Sciences.

Assessment of the Mulder and Van Doorn kinetic procedure and rapid centrifugal analysis of UDP-glucuronosyltransferase activities.

G. Siest, J. Boutin, J. Magdalou, 1984, Journal of biochemical and biophysical methods.

Effect of pretreatment with hydroxylated xenobiotics on the activities of rat liver UDP-glucuronosyl-transferases.

G. Siest, J. Boutin, A. Batt, 1983, Xenobiotica; the fate of foreign compounds in biological systems.

Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.

J. Boutin, F. Nepveu, J. Arbonés-Mainar, 2016, Chemico-biological interactions.

Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purification?

J. Boutin, 1987, Drug metabolism reviews.

Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide.

G. Siest, J. Boutin, A. Batt, 1984, Pharmacological research communications.

Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.

J. Nicolas, J. Boutin, D. Lesieur, 2002, Journal of medicinal chemistry.

Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference.

G. Ferry, J. Boutin, P. Delagrange, 2007, Biochimie.

Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries.

J. Fauchère, J. Boutin, J. Henlin, 1997, Canadian journal of physiology and pharmacology.

Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus)

O. Nosjean, J. Boutin, V. Simonneaux, 2018, PloS one.

Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

J. Boutin, P. Delagrange, R. Jockers, 2008, British journal of pharmacology.

Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands.

G. Ferry, J. Boutin, E. Canet, 2001, European journal of pharmacology.

Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis

Steven L. Coon, David C. Klein, Jean A. Boutin, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptors.

J. Nicolas, J. Boutin, F. Cogé, 1999, The Biochemical journal.

Truncated isoforms inhibit [ 3 H ] prazosin binding and cellular trafficking of native human α 1 A-adrenoceptors

J. Nicolas, J. Boutin, F. Cogé, 1999 .

Meganuclease-Driven Targeted Integration in CHO-K1 Cells for the Fast Generation of HTS-Compatible Cell-Based Assays

O. Nosjean, P. Duchateau, G. Ferry, 2010, Journal of biomolecular screening.

Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.

J. Boutin, P. Renard, P. Delagrange, 2011, European journal of medicinal chemistry.

Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors

Charles-Étienne Benoit, J. Boutin, R. Quirion, 2010, The Journal of Neuroscience.

Molecular and cellular pharmacological properties of 5‐methoxycarbonylamino‐N‐acetyltryptamine (MCA‐NAT): a nonspecific MT3 ligand

O. Nosjean, J. Boutin, P. Delagrange, 2010, Journal of pineal research.

Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis.

G. Ferry, J. Boutin, P. Delagrange, 2008, Archives of biochemistry and biophysics.

New Ligands at the Melatonin Binding Site MT3.

J. Boutin, 2006 .

Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells

Jean A. Boutin, J. Boutin, F. Cogé, 2011, PloS one.

Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides.

O. Nosjean, G. Ferry, J. Boutin, 2017, Analytical biochemistry.

8-Amino-5-nitro-6-phenoxyquinolines: Potential Non-peptidic Neuropeptide Y Receptor Ligands

J. Boutin, P. Renard, P. Pinson, 2002, Journal of Enzyme Inhibition and Medicinal Chemistry.

Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal

G. Ferry, J. Boutin, F. Cogé, 2007, FEBS letters.

Gene expression profiling during hibernation in the European hamster

Jean A Boutin, Célia Gautier, Damien Valour, 2018, Scientific Reports.

Expression and regulation of the nuclear receptor RORalpha in human vascular cells.

J. Boutin, J. Mariani, A. Tedgui, 2002, FEBS letters.

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

G. Ferry, J. Boutin, J. Hickman, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics S 49076 Is a Novel Kinase Inhibitor of MET , AXL , and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

G. Ferry, J. Boutin, J. Hickman, 2013 .

The active conformation of human glucokinase is not altered by allosteric activators.

R. Vincentelli, G. Ferry, L. Vuillard, 2011, Acta crystallographica. Section D, Biological crystallography.

Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.

A. Cavalli, G. Bottegoni, G. Ferry, 2016, Journal of medicinal chemistry.

Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery.

Catherine Vénien-Bryan, L. Vuillard, J. Boutin, 2017, Acta crystallographica. Section F, Structural biology communications.

Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries

G. Ferry, J. Boutin, Barbara Calamini, 2023, Receptors.

Biochemistry, structure, and cellular internalization of a four nanobody‐bearing Fc dimer

G. Ferry, J. Boutin, Eric Chabrol, 2021, Protein science : a publication of the Protein Society.

Drug-induced hydrogen peroxide production in isolated rat hepatocytes.

J. Boutin, G. Kass, P. Moldéus, 1989, Toxicology.

Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme

G. Ferry, J. Boutin, Barbara Calamini, 2020, Molecular Pharmacology.

Camphoroquinone reduction: another reaction catalyzed by rat liver cytosol 3 alpha-hydroxysteroid dehydrogenase.

J. Boutin, 1986, Biochimica et biophysica acta.

A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot

G. Ferry, L. Vuillard, J. Boutin, 2018, The Journal of Biological Chemistry.

High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes.

Jean A Boutin, O. Nosjean, J. Boutin, 2016, American journal of physiology. Heart and circulatory physiology.

Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries.

J. Fauchère, J. Boutin, W. Marande, 1999, Cellular signalling.

Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210.

G. Ferry, J. Boutin, M. Vincent, 1993, European journal of biochemistry.

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors

M. Millan, D. Cussac, A. Newman-Tancredi, 2008, Journal of Pharmacology and Experimental Therapeutics.

Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).

J. Boutin, M. Spedding, P. Renard, 2012, European journal of medicinal chemistry.

Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.

J. Boutin, D. Lesieur, P. Renard, 2009, Bioorganic & Medicinal Chemistry.

Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.

J. Boutin, D. Lesieur, P. Renard, 2008, Bioorganic & medicinal chemistry.

Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates

G. Ferry, J. Boutin, F. Nepveu, 2019, Molecules.

Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives

G. Ferry, J. Boutin, F. Nepveu, 2017, Molecules.

Murine and Human Autotaxin α, β, and γ Isoforms

G. Ferry, J. Boutin, P. Valet, 2008, Journal of Biological Chemistry.

High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1

J. Boutin, Ming-Wei Wang, X. Hao, 2008, Acta Pharmacologica Sinica.

Comparative analysis of melanin-concentrating hormone structure and activity in fishes and mammals

J. Boutin, B. Cardinaud, J. Nahon, 2004, Peptides.

SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor.

J. Fauchère, J. Nicolas, J. Boutin, 2002, Biochemical and biophysical research communications.

Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2.

J. Boutin, V. Audinot, J. Galizzi, 2001, Molecular pharmacology.

Structure-Activity Relationship Studies of Melanin-concentrating Hormone (MCH)-related Peptide Ligands at SLC-1, the Human MCH Receptor*

J. Fauchère, J. Boutin, V. Audinot, 2001, The Journal of Biological Chemistry.

Cloning and Molecular Characterization of the Novel Human Melanin-Concentrating Hormone Receptor MCH 2

J. Boutin, V. Audinot, J. Galizzi, 2001 .

Genomic organization and characterization of splice variants of the human histamine H 3 receptor

J. Boutin, F. Cogé, J. Galizzi, 2022 .

A Generic Approach for the Purification of Signaling Complexes That Specifically Interact with the Carboxyl-terminal Domain of G Protein-coupled Receptors*S

G. Ferry, J. Boutin, P. Delagrange, 2008, Molecular & Cellular Proteomics.

Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles.

O. Nosjean, G. Ferry, J. Boutin, 2016, Biochemistry.

Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist

É. Schmidt, J. Nicolas, J. Boutin, 2003, Cardiovascular Drugs and Therapy.

Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60.

G. Ferry, J. Boutin, J. Barret, 2009, International journal of peptide and protein research.

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

M. Millan, D. Cussac, A. Newman-Tancredi, 2002, Journal of Pharmacology and Experimental Therapeutics.

¹⁹F nuclear magnetic resonance screening of glucokinase activators.

G. Ferry, J. Boutin, M. Delsuc, 2015, Analytical biochemistry.

Is There Sufficient Evidence that the Melatonin Binding Site MT3 Is Quinone Reductase 2?

G. Ferry, J. Boutin, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: comparison between human and mammalian species activities.

G. Siest, J. Boutin, A. Batt, 1984, Chemico-biological interactions.

Quinone reductase 2 substrate specificity and inhibition pharmacology.

G. Ferry, J. Boutin, P. Delagrange, 2005, Chemico-biological interactions.

Respective contributions of α‐adrenergic and non‐adrenergic mechanisms in the hypotensive effect of imidazoline‐like drugs

J. Boutin, P. Renard, B. Pfeiffer, 2001, British journal of pharmacology.

UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species.

G. Siest, P. Marlière, J. Boutin, 1981, Biochemical pharmacology.

Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry

G. Ferry, J. Boutin, P. Delagrange, 2012 .

Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2‐adrenergic receptors (AR)s, serotonin (5‐HT)1A, 5‐HT1B, 5‐HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

M. Millan, D. Cussac, A. Gobert, 2000, Synapse.

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization

M. Millan, D. Cussac, A. Newman-Tancredi, 2012, Journal of Pharmacology and Experimental Therapeutics.

N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes.

G. Ferry, J. Boutin, M. Vincent, 1991, European journal of biochemistry.

Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA)

P. Svenningsson, M. Millan, A. Gobert, 2011, The Journal of Neuroscience.

Liquid chromatographic assay for the measurement of glucuronidation of arylcarboxylic acids using uridine diphospho-[U-14C] glucuronic acid.

G. Siest, J. Boutin, J. Magdalou, 1986, Journal of chromatography.

Studies of UDP-glucuronosyltransferase activity toward eugenol, using a gas chromatographic method of measurement.

G. Siest, J. Boutin, E. Solheim, 1983, Analytical biochemistry.

Molecular Characterization and Pharmacology of Melatonin Receptors in Animals

J. Boutin, E. Cecon, R. Jockers, 2023, Receptors.

Molecular mechanisms of transcriptional control by Rev‐erbα: An energetic foundation for reconciling structure and binding with biological function

G. Ferry, J. Boutin, C. Royer, 2015, Protein science : a publication of the Protein Society.

Minireviews Is There Sufficient Evidence that the Melatonin Binding Site MT 3 Is Quinone Reductase 2?

G. Ferry, J. Boutin, 2018 .

Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study

H. Vaudry, J. Boutin, J. Chuquet, 2021, Molecules.

Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative.

H. Vaudry, J. Boutin, J. Chuquet, 2018, Journal of medicinal chemistry.

Molecular basis of agonist docking in a human GPR103 homology model by site‐directed mutagenesis and structure–activity relationship studies

H. Vaudry, J. Boutin, J. Chuquet, 2014, British journal of pharmacology.

Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes

R. Ravid, G. Ferry, J. Boutin, 2007, Journal of pineal research.

Why Search for Alternative GPCR Agonists?

J. Boutin, J. Leprince, 2023, Receptors.

Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity.

G. Ferry, J. Boutin, A. Alpert, 1992, Journal of chromatography.

New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors

O. Nosjean, J. Boutin, P. Delagrange, 2013, International journal of molecular sciences.

A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction.

O. Nosjean, J. Boutin, M. Litaudon, 2009, Journal of natural products.

S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures.

J. Boutin, P. Lestage, J. Galizzi, 2007, European journal of pharmacology.

Partial purification and characterization of a new p36/40 tyrosine protein kinase from HL-60.

J. Boutin, A. Ernould, A. Genton, 1989, Biochemical and biophysical research communications.

A Chemical Library to Screen Protein and Protein–Ligand Crystallization Using a Versatile Microfluidic Platform

G. Ferry, L. Vuillard, J. Boutin, 2018, Crystal Growth & Design.

Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBα/NCoR

X. Barril, J. Boutin, P. Ducrot, 2017, Journal of Computer-Aided Molecular Design.

Development of new assays and improved procedures for the purification of recombinant human chymase.

G. Ferry, J. Boutin, L. Gillet, 2001, European journal of biochemistry.

Mutagenic analysis in a pure molecular system shows that thioredoxin‐interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin

G. Ferry, J. Boutin, F. Cogé, 2012, Protein science : a publication of the Protein Society.

Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo

G. Ferry, J. Boutin, J. Stojko, 2021, Molecular Biology Reports.

Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo

G. Ferry, J. Boutin, J. Stojko, 2021, Molecular Biology Reports.

A Simple Theoretical Model for Fluorescence Polarization Binding Assay Development

O. Nosjean, J. Boutin, C. Deniau, 2006, Journal of biomolecular screening.

Murine and Human Autotaxin , , and Isoforms GENE ORGANIZATION , TISSUE DISTRIBUTION , AND BIOCHEMICAL CHARACTERIZATION

G. Ferry, J. Boutin, P. Valet, 2008 .

A convenient 3-step synthesis of 3-acetamido-6-arylpyridazines directed to novel Y5 receptor antagonist.

C. Wermuth, J. Boutin, P. Renard, 2002, Chemical & pharmaceutical bulletin.

Combinatorial peptide libraries: robotic synthesis and analysis by nuclear magnetic resonance, mass spectrometry, tandem mass spectrometry, and high-performance capillary electrophoresis techniques.

J. Fauchère, J. Boutin, P. Lambert, 1996, Analytical Biochemistry.

Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6)

O. Nosjean, G. Ferry, L. Vuillard, 2016, Protein science : a publication of the Protein Society.

Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries

Jean A. Boutin, Ghanem Atassi, J. Fauchère, 2005, Molecular Diversity.

Approaches to some biochemical mechanisms of action of tuftsin and analogues.

G. Ferry, J. Boutin, M. Vincent, 1991, Biochemical pharmacology.

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor

M. Millan, D. Cussac, A. Newman-Tancredi, 2002, Journal of Pharmacology and Experimental Therapeutics.

Combinatorial peptide synthesis: statistical evaluation of peptide distribution.

J. Boutin, J A Boutin, A L Fauchère, 1996, Trends in pharmacological sciences.

Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes.

J. Boutin, P. Moldéus, G. Lavielle, 1989, European journal of cancer & clinical oncology.

Melanin-concentrating hormone receptors in GtoPdb v.2023.1

J. Boutin, V. Audinot, B. Lakaye, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Perfusion process for CHO cell producing monoclonal antibody: comparison of methods for determination of the optimum cell specific perfusion rate

G. Ferry, J. Boutin, C. Cabanne, 2022, Biochemical Engineering Journal.

Cloning and characterization of the 5' flanking region of the human uncoupling protein 3 (UCP3) gene.

J. Boutin, E. Canet, J. Galizzi, 1999, Biochemical and biophysical research communications.

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

M. Millan, D. Cussac, A. Gobert, 2000, The Journal of pharmacology and experimental therapeutics.

Structure activity relationship studies of MCH-related peptide ligands at SLC-1, the human melanin-concentrating hormone receptor.

J. Fauchère, J. Boutin, V. Audinot, 2001 .

the Medulla of Neurons in Superficial and Deeper Dorsal Horn of -Adrenoceptors Modulate NMDA-Evoked Responses

A. M. Peterson, E. Szabadi, M. Millan, 2015 .

The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells

O. Nosjean, M. Millan, J. Harper, 2019, Scientific Reports.

Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol

M. Millan, D. Cussac, A. Newman-Tancredi, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.

J. Boutin, A. Ktorza, B. Staels, 2009, Bioorganic & medicinal chemistry letters.

Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity

J. Boutin, A. Ktorza, B. Staels, 2012, ChemMedChem.

Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6)

O. Nosjean, G. Ferry, L. Vuillard, 2016, Protein science : a publication of the Protein Society.

In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters

G. Siest, J. Boutin, V. Loppinet, 1987 .

Receptor- and Ligand-Based Study on Novel 2, 2′-Bithienyl Derivatives as Non-Peptidic AANAT Inhibitors

Xiao Feng, Jana Sopkova-de Oliveira Santos, Ronan Bureau, 2010, J. Chem. Inf. Model..

A quantitative assay for lysosomal acidification rates in human osteoclasts.

O. Nosjean, M. Karsdal, J. Boutin, 2011, Assay and drug development technologies.